

BULGARIA

Recent and planned developments in pharmaceutical policies 2017/2018

Special topic: patient involvement in pricing and reimbursement of medicines

CHANGES IN PRICING

Freezing the registered prices of OTC products until December 31st, 2019 (Prices increase of OTC products is allowed only by the percentage of the inflation rate);

From January 1, 2018, a provision is in force whereby a medicinal product does not have a manufacturer's price in the reference countries, its price may not be higher than twice the lowest manufacturer's price of the medicinal product of the same INN and pharmaceutical form in PDL.

CHANGES IN REIMBURSEMENT

Not included in the Positive Drug List of combined medicinal products when one of the active ingredients is OTC;

Obligation to monitor the effect of therapy for the new medicinal products paid with public funds for the period of three years: these are the products for which there are no enough evidence for therapeutical effectiveness and/or cost/benefit ratio is not cost effective.

OTHERS CHANGES

No

SPECIAL TOPIC: Patient Involvement in Pricing and Reimbursement of Medicines

Please describe briefly if and how patients/citizens in your country are involved in:

Pricing and reimbursement procedures of medicines

- Do patients/citizens have the opportunity to raise their voice during medicines pricing and/or reimbursement procedures?

No

- Do patients also have the opportunity for participation in review/appeal processes?

Yes in appeal process.

Transparency Commission – 15 members incl. chairman, one of them is representative of patients organisations.

Related to HTA procedures

- Do patients have the opportunity to raise their voice in HTA procedures?

No